Rinaldi F - Search Results

1

Severe relapses under fingolimod treatment prescribed after natalizumab.

Centonze D, Rossi S, Rinaldi F, Gallo P. Centonze D, et al. Among authors: rinaldi f. Neurology. 2012 Nov 6;79(19):2004-5. doi: 10.1212/WNL.0b013e3182735c7a. Epub 2012 Oct 3. Neurology. 2012. PMID: 23035063 No abstract available.

2

Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.

Rinaldi F, Perini P, Calabrese M, Rinaldi L, Gallo P. Rinaldi F, et al. Among authors: rinaldi l. Mult Scler. 2009 Nov;15(11):1359-62. doi: 10.1177/1352458509107011. Epub 2009 Oct 7. Mult Scler. 2009. PMID: 19812116

3

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.

Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P. Rinaldi L, et al. Among authors: rinaldi f. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1345-50. doi: 10.1136/jnnp.2009.201079. Epub 2010 Jun 14. J Neurol Neurosurg Psychiatry. 2010. PMID: 20547618

4

No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab.

Margoni M, Rinaldi F, Riccardi A, Franciotta S, Perini P, Gallo P. Margoni M, et al. Among authors: rinaldi f. J Neurol. 2020 Jan;267(1):100-105. doi: 10.1007/s00415-019-09554-z. Epub 2019 Sep 27. J Neurol. 2020. PMID: 31562558

5

Widespread cortical thinning characterizes patients with MS with mild cognitive impairment.

Calabrese M, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Romualdi C, Rinaldi L, Perini P, Gallo P. Calabrese M, et al. Among authors: rinaldi f, rinaldi l. Neurology. 2010 Jan 26;74(4):321-8. doi: 10.1212/WNL.0b013e3181cbcd03. Neurology. 2010. PMID: 20101038

6

The predictive value of gray matter atrophy in clinically isolated syndromes.

Calabrese M, Rinaldi F, Mattisi I, Bernardi V, Favaretto A, Perini P, Gallo P. Calabrese M, et al. Among authors: rinaldi f. Neurology. 2011 Jul 19;77(3):257-63. doi: 10.1212/WNL.0b013e318220abd4. Epub 2011 May 25. Neurology. 2011. PMID: 21613600

7

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.

Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P. Rinaldi F, et al. Mult Scler. 2012 Dec;18(12):1760-7. doi: 10.1177/1352458512447704. Epub 2012 May 8. Mult Scler. 2012. PMID: 22570359 Clinical Trial.

8

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Rinaldi F, et al. Mult Scler. 2012 Nov;18(11):1640-3. doi: 10.1177/1352458512464282. Mult Scler. 2012. PMID: 23100526

9

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.

Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M. Calabrese M, et al. Among authors: rinaldi f, rinaldi l. Arch Neurol. 2009 Sep;66(9):1144-50. doi: 10.1001/archneurol.2009.174. Arch Neurol. 2009. PMID: 19752305

10

No MRI evidence of cortical lesions in neuromyelitis optica.

Calabrese M, Oh MS, Favaretto A, Rinaldi F, Poretto V, Alessio S, Lee BC, Yu KH, Ma HI, Perini P, Gallo P. Calabrese M, et al. Among authors: rinaldi f. Neurology. 2012 Oct 16;79(16):1671-6. doi: 10.1212/WNL.0b013e31826e9a96. Epub 2012 Sep 19. Neurology. 2012. PMID: 22993282

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

548 results

Search Page

Filters